Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

14 juil. 2026 11h59 HE | Source: Research and Markets

Helicobacter Pylori Infection Market to Reach USD 720 Million by 2036 As Resistance-Targeted Therapies Gain Ground

Dublin, July 14, 2026 (GLOBE NEWSWIRE) -- The "Helicobacter Pylori (H. Pylori) Infection - Market Insights, Epidemiology, and Market Forecast - 2036" has been added to ResearchAndMarkets.com's...
13 juil. 2026 04h00 HE | Source: AKAMPION

Omnix Medical Launches New Horizon Europe PEPTAMR Infectious Disease Consortium

Omnix Medical Launches EUR ~8M Horizon Europe PEPTAMR Infectious Disease Consortium to Advance Lead Program OMN6 Toward Clinical Phase III
30 juin 2026 04h00 HE | Source: smartbax GmbH

smartbax secures additional financing to advance lead antibiotic program to IND filing

Munich, Germany, June 30, 2026 (GLOBE NEWSWIRE) -- smartbax, a biotech company developing next-generation antibiotics against multi-drug resistant bacteria, today announced the successful second...
28 avr. 2026 03h52 HE | Source: Mordor Intelligence

Antibiotic Resistance Market to Grow at 5.4% CAGR Reaching USD 12.72 Billion by 2031, Driven by Rising Drug-Resistant Infections and Antimicrobial Innovation: Mordor Intelligence

Hyderabad, India, April 28, 2026 (GLOBE NEWSWIRE) -- According to the latest report by Mordor Intelligence, the antibiotic resistance market size is estimated at USD 9.78 billion in 2026, up from...
19 avr. 2026 08h00 HE | Source: Fedora Pharmaceuticals, Inc.

Fedora Pharmaceuticals Presentations at 2026 ESCMID Highlight Safety and Potent Bactericidal Activity of FPI-2119

EDMONTON, Alberta , April 19, 2026 (GLOBE NEWSWIRE) -- Fedora Pharmaceuticals, Inc., a leader in the development of drugs to treat antibiotic-resistant infections, is presenting a full suite of...
14 avr. 2026 05h16 HE | Source: Research and Markets

Antimicrobial Resistance (AMR) and 'One Health' Framework Course: Current Challenges, Regulatory Frontiers and Future Solutions (ONLINE EVENT: June 10, 2026)

Dublin, April 14, 2026 (GLOBE NEWSWIRE) -- The "Antimicrobial Resistance (AMR) and 'One Health': Current Challenges, Regulatory Frontiers and Future Solutions (June 10, 2026)" training has been...
09 avr. 2026 08h30 HE | Source: Fedora Pharmaceuticals, Inc.

Fedora Pharmaceuticals Showcasing Antibiotic Candidate at 2026 European Society of Clinical Microbiology and Infectious Diseases Congress

EDMONTON, Alberta , April 09, 2026 (GLOBE NEWSWIRE) -- Fedora Pharmaceuticals, Inc., a leader in the development of drugs to treat antibiotic-resistant infections, intends to present a full suite of...
12 févr. 2026 07h30 HE | Source: MicrobiotiX

MicrobiotiX and West Africa Centre for Innovative Research and Care Formalize Landmark Phage Therapy Collaboration in Ghana

MicrobiotiX and WAFCIRC sign MoU and Research Collaboration Agreement in Ghana, launching clinical research to evaluate phage therapy for AMR infections.
29 janv. 2026 08h12 HE | Source: Fedora Pharmaceuticals, Inc.

Fedora Pharmaceuticals Highlights Efficacy of Novel Antibiotic, FPI-2119, against Antimicrobial-resistant Gram-negative Bacteria at the 2026 IMARI Conference

EDMONTON, Alberta , Jan. 29, 2026 (GLOBE NEWSWIRE) -- Fedora Pharmaceuticals, Inc., a leader in the development of drugs to treat antibiotic-resistant infections, is presenting four posters at the...
20 janv. 2026 04h00 HE | Source: smartbax GmbH

smartbax in-licenses lead antibacterial compound targeting Gram-negative infections from Aicuris

Munich, Germany, Jan. 20, 2026 (GLOBE NEWSWIRE) -- smartbax, a biotech company developing next-generation antibiotics against multi-drug resistant bacteria, today announced the in-licensing of a new...

Page suivante